Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma

Gilles Salles, MD PhD, Martin J.S. Dyer, MA, DPhil, FRCP, FRCPath, Daniel James Hodson, MD PhD, Krimo Bouabdallah, MD, Loic Ysebaert, MD PhD, Guillaume Cartron, Andrew John Davies, PhD, Alexey V Danilov, MD PhD, Christopher Fegan, MD, Ebenezer A Kio, MD, Xi Huang, PhD, Siddhartha Mitra, MD PhD, Simon Rule, MD, Franck Morschhauser, MD

Blood (2018) 132 (Supplement 1): 5344.

https://doi.org/10.1182/blood-2018-99-113115

Published: 2018

Journal Articles

Ibrutinib Plus Obinutuzumab and Venetoclax in Relapsed/Refractory Mantle Cells Lymphoma Patients, Results of the OASIS Phase I Clinical Trial

Steven Le Gouill, MD PhD, Franck Morschhauser, MD, Krimo Bouabdallah, MD, Guillaume Cartron, Rene-Olivier Casasnovas, MD, Noel-Jean Milpied, MD, Thomas Gastinne, MD, Andrew John Davies, PhD, Charles Herbaux, MD, David Chiron, PhD, Mary Callanan, PhD, Simon Rule, MD

Blood (2018) 132 (Supplement 1): 4158.

https://doi.org/10.1182/blood-2018-99-113777

Published: 2018

Journal Articles

A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial

Mary Gleeson, Nicholas Counsell, David Cunningham, Eliza Hawkes, Anthony Lawrie, Andrew Jack, Paul Smith, Christopher Pocock, MD PhD, Kirit M. Ardeshna, MB BChir, John Radford, MD FRCP, Andrew McMillan, John Davies, Deborah Turner, Anton Kruger, Peter Johnson, MD, David C. Linch

Blood (2018) 132 (Supplement 1): 2956.

https://doi.org/10.1182/blood-2018-99-111824

Published: 2018

Journal Articles

The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial

Blood (2016) 128 (22): 1746.

https://doi.org/10.1182/blood.V128.22.1746.1746

Published: 2016

Journal Articles

Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Small Lymphocytic Lymphoma (SLL)

Ajay K Gopal, MD, Andrew John Davies, BM, PhD, Ian W. Flinn, MD PhD, Paolo Ghia, MD PhD, Andre Goy, MD, Gilles A. Salles, MD PhD, Steve Abella, MD, Betsy Philip, Bess Sorenson, Nina D. Wagner-Johnston, MD

Blood (2015) 126 (23): 2743.

https://doi.org/10.1182/blood.V126.23.2743.2743

Published: 2015

Journal Articles

Idelalisib Treatment Is Associated with Improved Cytopenias in Patients with Relapsed/Refractory iNHL and CLL

Susan O'Brien, MD, Andrew John Davies, BM, PhD, Ian W. Flinn, MD PhD, Ajay K Gopal, MD, Thomas J. Kipps, MD, PhD, Gilles A. Salles, MD PhD, Terry Newcomb, PhD, Christopher C. Waldapfel, Zhihai Zhang, Stephan Stilgenbauer, MDPhD

Blood (2015) 126 (23): 1747.

https://doi.org/10.1182/blood.V126.23.1747.1747

Published: 2015

Journal Articles

Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial

Blood (2015) 126 (23): 1516.

https://doi.org/10.1182/blood.V126.23.1516.1516

Published: 2015

Journal Articles

Risk of CNS Relapse with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Trial

Mary Gleeson, FRCPath, David Cunningham, FMedSci, Eliza A Hawkes, MD, Wendi Qian, PhD, Paul Smith, MSc, Nick Chadwick, Paul Mouncey, MSc, Andrew Jack, PhD, Christopher Pocock, MD PhD, Kirit M Ardeshna, MD FRCPath, John Radford, Andrew McMillan, PhD, John Davies, FRCPE, Deborah Turner, FRCPath, Anton Kruger, FRCPath, Peter W.M. Johnson, FRCP, Joanna Gambell, BSc, David C Linch, FMedSci

Blood (2014) 124 (21): 1723.

https://doi.org/10.1182/blood.V124.21.1723.1723

Published: 2014

Journal Articles

Prognostic Effect Of More Than 1 Extranodal Site Of Disease For Patients With Diffuse Large B Cell Lymphoma (DLBCL) In The Rituximab Era: Results From The UK NCRI R-CHOP 14 Versus 21 Trial

Mary Gleeson, FRCPath, Wendi Qian, PhD, David Cunningham, FMedSci, Eliza Hawkes, FRACP, Andrew Jack, PhD, Paul Smith, MSc, Paul Mouncey, MSc, Christopher Pocock, PhD, Kirit M Ardeshna, FRCPath, John Radford, MD, Andrew McMillan, FRCPath, John Davies, FRCPE, Deborah Turner, FRCPath, Anton Kruger, FRCPath, Peter Johnson, FRCP, Joanna Gambell, BSc, David Linch, FMedSci

Blood (2013) 122 (21): 4268.

https://doi.org/10.1182/blood.V122.21.4268.4268

Published: 2013

Journal Articles

An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic, Non-Bulky Follicular Lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis

Kirit M Ardeshna, MD, Wendi Qian, Paul Smith, June Warden, Lindsay Stevens, Christopher FE Pocock, MD, PhD, Fiona Miall, MD, David Cunningham, MD, John Davies, MD, Jan Walewski, A. Burhan Ferhanoglu, MD, Ken Bradstock, MB, PhD, David C Linch, MD, FMedSci

Blood (2010) 116 (21): 6.

https://doi.org/10.1182/blood.V116.21.6.6

Published: 2010

Journal Articles

Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation

Michal Sieniawski, Nithia Angamuthu, Kathryn Boyd, Richard Chasty, John Davies, Peter Forsyth, Fergus Jack, Simon Lyons, Philip Mounter, Paul Revell, Stephen J. Proctor, Anne L. Lennard

Blood (2010) 115 (18): 3664–3670.

https://doi.org/10.1182/blood-2009-07-231324

Published: 2010

Journal Articles

Duration of First Remission in Diffuse Large B-Cell Lymphoma (DLBCL) Define Groups of Patients with Different Overall Survival Which Cannot Be Entirely Distinguished by Clinical Features or IPI at Diagnosis: a Prospective Population Based Study of the Scotland and Newcastle Lymphoma Group

Michal Sieniawski, Jennifer Wilkinson, Dominic Culligan, John Davies, John Goodlad, Ruth Jarrett, Anne L Lennard, Helen Lucraft, Tryfonia Mainou-Fowler, Pam McKay, Fiona Scott, Sudhir Tauro, Jo White, Stephen J Proctor

Blood (2008) 112 (11): 2604.

https://doi.org/10.1182/blood.V112.11.2604.2604

Published: 2008

Journal Articles

Sequential Evaluation of Outcome in Enteropathy Associated T Cell Lymphoma Comparing Standard Therapeutic Approaches – Surgery or CHOP-Like Chemotherapy with a New High Dose Ifosfamide/Methotrexate and Autologous Stem Cell Transplant Regimen: A Prospective Study of Scotland and Newcastle Lymphoma Group

Michal Sieniawski, MD, Nithia Angamuthu, Kathryn Boyd, Richard Chasty, John Davies, Paul Revell, Stephen J Proctor, Anne L Lennard

Blood (2008) 112 (11): 578.

https://doi.org/10.1182/blood.V112.11.578.578

Published: 2008

NARROW

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma

Ibrutinib Plus Obinutuzumab and Venetoclax in Relapsed/Refractory Mantle Cells Lymphoma Patients, Results of the OASIS Phase I Clinical Trial

A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial

The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial

Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Small Lymphocytic Lymphoma (SLL)

Idelalisib Treatment Is Associated with Improved Cytopenias in Patients with Relapsed/Refractory iNHL and CLL

Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial

R-CHOP in Primary Mediastinal B-Cell Lymphoma (PMBL): Results from the UK NCRI R-CHOP 14 v 21 Trial

Risk of CNS Relapse with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Trial

Prognostic Effect Of More Than 1 Extranodal Site Of Disease For Patients With Diffuse Large B Cell Lymphoma (DLBCL) In The Rituximab Era: Results From The UK NCRI R-CHOP 14 Versus 21 Trial

An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic, Non-Bulky Follicular Lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis

Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation

Duration of First Remission in Diffuse Large B-Cell Lymphoma (DLBCL) Define Groups of Patients with Different Overall Survival Which Cannot Be Entirely Distinguished by Clinical Features or IPI at Diagnosis: a Prospective Population Based Study of the Scotland and Newcastle Lymphoma Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only